Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. Academic Article uri icon

Overview

abstract

  • To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.

publication date

  • November 2, 2021

Research

keywords

  • Hepacivirus
  • Hepatitis C

Identity

PubMed Central ID

  • PMC8563211

Scopus Document Identifier

  • 85120420059

Digital Object Identifier (DOI)

  • 10.1093/cid/ciaa362

PubMed ID

  • 32282879

Additional Document Info

volume

  • 73

issue

  • 9